AV-1980R/A / Capo Therap - LARVOL DELTA

First-in-human AV-1980R/A tau vaccine for Alzheimer's prevention (IND 29644) (CTAD 2024) - No abstract available

P1 data • Alzheimer's Disease • CNS Disorders

PHASE 1 PREVENTIVE ADJUVANTED TAU VACCINE, AV-1980R (ADPD 2023) - "For example, treatment with the anti-amyloid fibril mAb lecanemab reduced attenuates cognitive decline; and these mAbs in general decrease plasma, CSF, and brain p-tau and tau. Conclusions Immunogenically active, safe, and effective vaccines are ideal candidates for preventative therapy in cognitively unimpaired people for inhibiting accumulation of tau pathology and potentially delaying illness onset. We are evaluating for the first-time a preventive vaccine, AV-1980R/A targeting the phosphatase-activating domain ( PAD) of pathological tau."

Clinical • IO biomarker • P1 data • Alzheimer's Disease • CNS Disorders • Hematological Disorders • Aβ42 • GFAP • NEFL • p-tau181

IMMUNOGENICITY OF MULTITEP PLATFORM TECHNOLOGY-BASED TAU VACCINE IN NON-HUMAN PRIMATES: PRELUDE TO CLINICAL TRIALS (ADPD 2023) - "Lon Schneider's presentation). We hypothesize that vaccination of cognitively unimpaired people at risk of AD with AV-1980R/A can produce antibodies that will bind PAD of extracellular Tau and reduce the propagation of this early pathological molecule in the brain, thus delaying the onset of dementia."

Clinical • Alzheimer's Disease • CNS Disorders • Dementia • CRP

Phase 1 Preventive Adjuvanted Tau Vaccine, AV-1980R (CTAD 2022) - "A recent report stated that treatment with anti-amyloid mAb lecanemab reduced cognitive decline by 0.45 CDR-SB points. Passive mAb immunotherapy for cognitively unimpaired people is impractical due to the complexity and need for frequent administration of very high doses. Safe and immunogenic active vaccines are suitable candidates for preventing the accumulation of tau pathology and potentially delaying onset of illness. We are evaluating for the first-time preventive vaccine, AV-1980R/A targeting the phosphatase-activating domain (PAD) of pathological tau."

Clinical • IO biomarker • Late-breaking abstract • P1 data • Alzheimer's Disease • CNS Disorders • Hematological Disorders • GFAP • NEFL • Plasma Aβ42